ENTITY

Insilico Medicine (3696 HK)

69
Analysis
Health Care • Hong Kong
Insilico Medicine is an artificial intelligence (AI)-based biotechnology company that applies AI solutions to drug discovery and development, leveraging its proprietary Pharma.AI platform to identify and design early-stage drug candidates. The company develops novel drugs for various diseases, including cancer, fibrosis, immunity, and central nervous system disorders, and predicts clinical trial outcomes. Insilico Medicine was founded in 2014 and is headquartered in New Territories, Hong Kong.
more
•18 Dec 2025 12:57

Insilico Medicine Pre-IPO - An Emerging AI-Enabled Drug Discovery Platform

Insilico is a global drug discovery & development company that leverages its proprietary AI platform, to identify & design early-stage drug...

Logo
926 Views
Share
•16 Dec 2025 08:55

Pre-IPO InSilico Medicine (PHIP Updates) - Some Points Worth the Attention

Positioned as AI-biotech,​Insilico has to sell pipeline for cash as AI pharmaceuticals face challenge in commercialization and skepticism from...

Logo
780 Views
Share
•15 Aug 2026 21:48

China Healthcare Weekly Wrap (10-14 Aug)

1) LEGN 2Q results: Cavykti QoQ growth; in vivo CAR-T updates in 2H; 2) Jacobio profit alert on license income: AZ (pan-KRAS) and Allist (KRAS G12C...

Logo
110 Views
Share
•13 Aug 2026 09:50

HONG KONG ALPHA PORTFOLIO: (July 2026)

We made several adjustments to the portfolio yesterday. We sold the Baidu (9888) position since it hit our stop-loss level. We also sold the...

Logo
164 Views
Share
•12 Aug 2026 13:10

CHINA/HK: AI & RX - Together At Last !!

China's AI-driven drug discovery (AIDD) sector is growing rapidly, with leading drug and biotech companies entering R&D and drug-development...

Logo
112 Views
Share
x